Proclaim™ DRG Neurostimulator System for the Management of Chronic, Intractable Pain

Abstract

Chronic pain is consistently listed as one of the most costly and disabling health problems worldwide. In an effort to treat these suffering individuals, significant amounts of time and energy have been devoted to discover safe and effective pain relieving treatments. Dorsal root ganglion stimulation is the newest treatment modality to be created for chronic intractable pain. In this manuscript, we review the history and development, published research and safety profile of the Proclaim™ DRG Neurostimulator System (Abbott, TX, USA). At last, we offer our outlook on future developments with dorsal root ganglion stimulation.

Keywords::

• chronic pain
• dorsal root ganglion
• DRG
• neurostimulation

Financial & competing interests disclosure

TR Deer is a consultant for Abbott, Vertos, Axonics, Flowonix, Saluda Medical, SpineThera, Nalu, Cornerloc, SPR Therapeutics and Vertiflex. TR Deer is a member of the advisory board for Abbott, Flowonix, Nalu, SPR Therapeutics and Vertiflex. TR Deer has equity options in Bioness, Vertiflex, Axonics, Vertos, SpineThera, Saluda Medical, Nalu and Cornerloc. TR Deer is a research consultant for Abbott, Mainstay Medical, Saluda Medical, SPR Therapeutics and Vertiflex. TR Deer has a patent pending for the DRG paddle lead with Abbott. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.